Results 251 to 260 of about 193,906 (268)

Phosphoinositide-3-kinase (PI3K) inhibitors: Identification of new scaffolds using virtual screening

Bioorganic & Medicinal Chemistry Letters, 2009
In the present work, we used virtual screening (VS) of the ZINC database of 2.5 million compounds to seek new PI3K inhibitory scaffolds. The VS flowchart implemented various filters, including a 3D-database screen, and extensive docking studies, to derive 89 derivatives that were experimentally assayed against the four PI3K isoforms.
Raphaël, Frédérick, Claire, Mawson, Jackie D, Kendall, Claire, Chaussade, Gordon W, Rewcastle, Peter R, Shepherd, William A, Denny   +6 more
openaire   +2 more sources

Rationalizing Predictions of Isoform-Selective Phosphoinositide 3-Kinase Inhibitors Using MolAnchor Analysis

Journal of Chemical Information and Modeling
Explaining the predictions of machine learning models is of critical importance for integrating predictive modeling in drug discovery projects. We have generated a test system for predicting isoform selectivity of phosphoinositide 3-kinase (PI3K) inhibitors and systematically analyzed correct predictions of selective inhibitors using a new methodology ...
Alec Lamens, Jürgen Bajorath
openaire   +2 more sources

Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability

Bioorganic & Medicinal Chemistry, 2015
Phosphoinositide 3-kinase (PI3K) is activated in various human cancer cells and well known as a cancer therapy target. We previously reported a dihydropyrrolopyrimidine derivative as a highly potent PI3K inhibitor that has strong tumor growth inhibition in a xenograft model.
Hatsuo, Kawada, Hirosato, Ebiike, Masao, Tsukazaki, Shun, Yamamoto, Kohei, Koyama, Mitsuaki, Nakamura, Kenji, Morikami, Kiyoshi, Yoshinari, Miyuki, Yoshida, Kotaro, Ogawa, Nobuo, Shinma, Takuo, Tsukuda, Jun, Ohwada   +12 more
openaire   +2 more sources

Preventive and Therapeutic Effects of Phosphoinositide 3-Kinase Inhibitors on Acute Lung Injury

Chest, 2011
Phosphoinositide 3-kinases (PI3Ks) are involved in a number of biologic responses. Recent preclinical studies demonstrated that the PI3K-dominant signal pathway could play an important role in the development of acute lung injury, although the mechanism remains unclear.CD-1 mice were administered different PI3K inhibitors either intranasally or ...
Chengshui, Chen, Xiaocong, Fang, Yaoli, Wang, Yuping, Li, Diane, Wang, Xia, Zhao, Chunxue, Bai, Xiangdong, Wang   +7 more
openaire   +2 more sources

Molecular explorations of substituted 2-(4-phenylquinolin-2-yl) phenols as phosphoinositide 3-kinase inhibitors and anticancer agents

Cancer Chemotherapy and Pharmacology, 2017
M. Alagumuthu, S. Arumugam
semanticscholar   +1 more source

Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511.

Journal of Medicinal Chemistry, 2012
M. H. Norman, K. Andrews, Yunxin Y Bo, S. Booker, S. Caenepeel, V. Cee, Noel D'angelo, Daniel J. Freeman, B. Herberich, Fang-Tsao Hong, Claire L M Jackson, Jian Jiang, B. Lanman, Longbin Liu, J. McCarter, E. Mullady, N. Nishimura, L. Pettus, Anthony B. Reed, T. S. Miguel, A. Smith, Markian M Stec, Seifu Tadesse, A. Tasker, Divesh Aidasani, Xiaochun Zhu, R. Subramanian, N. Tamayo, Ling Wang, D. Whittington, Bin Wu, Tian Wu, Ryan P. Wurz, Kevin C Yang, Leeanne P Zalameda, Nancy Zhang, P. Hughes   +36 more
semanticscholar   +1 more source

Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft models.

Journal of Medicinal Chemistry, 2006
T. Zhu, J. Gu, Ker Yu, J. Lucas, P. Cai, R. Tsao, Yumin Gong, Fangbiao Li, Inder Chaudhary, Parimal Desai, M. Ruppen, M. Fawzi, J. Gibbons, S. Ayral-Kaloustian, J. Skotnicki, T. Mansour, A. Zask   +16 more
semanticscholar   +1 more source

Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) delta and gamma.

Current topics in medicinal chemistry, 2009
In recent years, pharmaceutical companies have increasingly focused on phosphoinositide 3-kinases delta (PI3Kdelta) and gamma (PI3Kgamma) as therapeutic targets for the treatment of inflammatory and autoimmune diseases. All class 1 PI3-kinases (alpha/beta/gamma/delta) generate phospholipid second messengers that help govern cellular processes such as ...
Michael K, Ameriks, Jennifer D, Venable
openaire   +1 more source

The effect of phosphoinositide 3-kinase inhibitors on programmed nuclear degradation in Tetrahymena and fate of surviving nuclei

Cell Death and Differentiation, 2004
J. Yakisich, G. Kapler
semanticscholar   +1 more source

The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).

Journal of Medicinal Chemistry, 2016
Timothy Heffron, R. Heald, Chudi O. Ndubaku, Binqing Wei, Martin Augistin, Steven Do, K. Edgar, C. Eigenbrot, L. Friedman, E. Gancia, P. Jackson, G. Jones, A. Kolesnikov, Leslie B. Lee, J. Lesnick, C. Lewis, N. Mclean, Mario Mörtl, J. Nonomiya, Jodie Pang, Steve Price, W. Prior, L. Salphati, S. Sideris, S. Staben, S. Steinbacher, V. Tsui, J. Wallin, D. Sampath, A. Olivero   +29 more
semanticscholar   +1 more source